Kenneth Carl Anderson - Net Worth and Insider Trading

Kenneth Carl Anderson Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kenneth Carl Anderson owns 1 companies in total, including C4 Therapeutics Inc (CCCC) .

Click here to see the complete history of Kenneth Carl Anderson’s form 4 insider trades.

Insider Ownership Summary of Kenneth Carl Anderson

Ticker Comapny Transaction Date Type of Owner
CCCC C4 Therapeutics Inc 2020-10-01 director

Kenneth Carl Anderson Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Kenneth Carl Anderson Ownership Network

Ownership Network List of Kenneth Carl Anderson

No Data

Ownership Network Relation of Kenneth Carl Anderson

Insider Network Chart

Kenneth Carl Anderson Owned Company Details

What does C4 Therapeutics Inc do?

Who are the key executives at C4 Therapeutics Inc?

Kenneth Carl Anderson is the director of C4 Therapeutics Inc. Other key executives at C4 Therapeutics Inc include Chief Financial Officer Kendra Adams , Chief Accounting Officer Mark Mossler , and Chief Medical Officer Leonard Reyno .

C4 Therapeutics Inc (CCCC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of C4 Therapeutics Inc (CCCC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of C4 Therapeutics Inc (CCCC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

C4 Therapeutics Inc (CCCC)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

C4 Therapeutics Inc Insider Transactions

No Available Data

Kenneth Carl Anderson Mailing Address

Above is the net worth, insider trading, and ownership report for Kenneth Carl Anderson. You might contact Kenneth Carl Anderson via mailing address: C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown Ma 02472.

Discussions on Kenneth Carl Anderson

No discussions yet.